Allergen Or Component Thereof (e.g., Ragweed Pollen, Etc.) Patents (Class 424/275.1)
-
Publication number: 20130309261Abstract: The present invention relates to a polypeptide comprising the amino acid sequence as shown in SEQ ID NO:9 or 7. The invention further pertains to nucleic acids encoding the polypeptide, pharmaceutical compositions and vaccines.Type: ApplicationFiled: November 30, 2011Publication date: November 21, 2013Applicant: Biomay AGInventors: Kuan-Wei Chen, Susanne Vrtala, Rudolf Valenta
-
Publication number: 20130302374Abstract: The present invention comprises methods and compositions for immunotherapy. An aspect of the invention comprises administration of one or more allergens in compositions via oral and sublingual routes. Allergen compositions are administered in dosing intervals wherein the increase in the one or more allergens administered to the patient are provided in increasing volumes of a single concentration of at least one allergen.Type: ApplicationFiled: July 19, 2013Publication date: November 14, 2013Applicant: GREER LABORATORIES, INC.Inventor: Robert E. Esch
-
Publication number: 20130302375Abstract: The invention describes a method and compounds for the prevention and treatment of infections with intracellular organisms, the treatment of tumors, and the prevention of infectious and allergic diseases by vaccination.Type: ApplicationFiled: November 24, 2011Publication date: November 14, 2013Applicant: IMNATE SARLInventor: Jean-Marie Saint-Remy
-
Publication number: 20130295139Abstract: The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE.Type: ApplicationFiled: March 13, 2013Publication date: November 7, 2013Inventor: Carl J. WHEELER
-
Publication number: 20130295147Abstract: Gas-filled microvesicles comprising an antigen bound thereto and to aqueous suspensions containing said microvesicles, for use in immunomodulating formulations, in particular as a vaccine. The antigen is covalently bound to a component of the microvesicles envelope. The microvesicles of the invention are particularly effective in the uptake by antigen-presenting cells, in particular dendritic cells.Type: ApplicationFiled: December 21, 2011Publication date: November 7, 2013Applicant: BRACCO SUISSE S.A.Inventors: Gilles Bioley, Blaise CH Corthesy, Philippe Bussat, Anne Lassus, Michel Schneider
-
Publication number: 20130295140Abstract: A composition of an olfactory stimulus mechanism for stimulating the production of testosterone. A method of increasing the level of testosterone in an individual by smelling the truffle extract, causing androgens in the truffle extract to attach to the olfactory bulb in the individual, and inducing testosterone production. A method of preventing the onset of Alzheimer's disease in an individual by the individual smelling the truffle extract, and inducing testosterone production in the individual. A method of treating symptoms of menopause in a woman by the woman smelling the truffle extract, and inducing testosterone production in the woman. A method of treating andropause in a man by a man smelling the truffle extract, and inducing testosterone production in the man.Type: ApplicationFiled: April 17, 2013Publication date: November 7, 2013Inventor: Moshe Shifrine
-
Publication number: 20130280302Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).Type: ApplicationFiled: June 3, 2011Publication date: October 24, 2013Inventors: Heather Michelle Webster, Jason Daniel Frey, Trena Larissa Repp, Craig T. Grass, David Rowles, Gary Steven Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Artega Vazquez, Juan Carlos Moreno Segura, Maria Jose Chamorro Salillas
-
Patent number: 8551491Abstract: The present invention relates to processes for the preparation of a batch of an active pharmaceutical ingredient, e.g. an allergen product. The invention also relates to a container comprising cryogranules of a liquid composition of an allergen product, and to a cryogranule of an allergen product. The processes feature formation of cryogranules using a container having therein a cryogenic medium (e.g. liquid nitrogen) and storage of the cryogranules in the same container. The cryogranules obtained can be stored and handled without prior freeze-drying.Type: GrantFiled: November 12, 2010Date of Patent: October 8, 2013Assignee: Alk-Abello A/SInventors: Martin Richter-Friis, Signe Andersen Kolmos
-
Patent number: 8551501Abstract: The present invention relates to chitin microparticles and their medical uses, in particular in the treatment of allergy, or the treatment of conditions that would benefit from an upregulation of the cell mediated immune system, or an up-regulation of natural killer (NK) cell activity and/or the secretion of interferon-? (IFN-?).Type: GrantFiled: August 21, 2008Date of Patent: October 8, 2013Assignee: Mucovax Inc.Inventor: Peter Strong
-
Patent number: 8551492Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.Type: GrantFiled: May 30, 2008Date of Patent: October 8, 2013Assignee: Circassia LimitedInventors: Roderick Peter Hafner, Mark Larche, Anthony Barrington Kay
-
Patent number: 8541000Abstract: The present invention relates to a new variant of the group 2 allergen from the house dust mite Dermatophagoides pteronyssinus, named Der p 2 variant, and uses thereof. The new variant exhibits cDNA and protein sequence diversity from other known Der p 2 variants.Type: GrantFiled: December 30, 2008Date of Patent: September 24, 2013Inventors: Kaw Yan Chua, Keh-Liang Lin, I-Chun Kuo, Chiung-Hui Huang
-
Patent number: 8540999Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.Type: GrantFiled: August 30, 2004Date of Patent: September 24, 2013Assignee: Merck Patent GmbHInventors: Irwin J. Griffith, Joanne Pollock, Julian F. Bond, Richard D. Garman, Mei-Chang Kuo, Stephen P. Powers, Mark A. Exley, Xian Chen, Ze'ev Shaked
-
Publication number: 20130243798Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.Type: ApplicationFiled: February 15, 2011Publication date: September 19, 2013Applicant: CIRCASSIA LIMITEDInventors: Christopher Hugh Reginald Stocker, Paul Laidler, Mark Larche, Roderick Peter Hafner
-
Publication number: 20130230551Abstract: Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against an a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed.Type: ApplicationFiled: December 20, 2012Publication date: September 5, 2013Inventors: Bin Wang, Huali Jin, Youmin Kang, Hsien-Jue Chu, Terry Kaleung NG
-
Patent number: 8524242Abstract: A soluble aggregate of allergen proteins, prepared by heating multiple allergen proteins and aggregating the allergen proteins and thus enclosing the antigen structures causing allergic reactions therein.Type: GrantFiled: May 7, 2010Date of Patent: September 3, 2013Assignees: Wako Filter Technology Co., Ltd., Protec Co., Ltd.Inventors: Akira Saito, Akio Kato
-
Publication number: 20130224251Abstract: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.Type: ApplicationFiled: December 17, 2010Publication date: August 29, 2013Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNGInventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
-
Publication number: 20130216581Abstract: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.Type: ApplicationFiled: March 15, 2013Publication date: August 22, 2013Inventor: Yale University
-
Publication number: 20130216582Abstract: The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral cavity (e.g. sublingual mucosa) combined with the administration of the unrelated antigen to either the respiratory tract, gastro-intestinal tract or skin in a simultaneous, contemporaneous, separate or sequential manner is provided.Type: ApplicationFiled: October 14, 2011Publication date: August 22, 2013Applicant: ALK-ABELLO A/SInventors: Jens Brimnes, Kaare Lund
-
Publication number: 20130218132Abstract: Infant pacifiers, compositions, and methods of use thereof, for preventing or reducing risk of developing a hyperallergenic immune system or allergic condition are provided.Type: ApplicationFiled: May 2, 2011Publication date: August 22, 2013Applicant: Apellis Pharmaceuticals, Inc.Inventor: Cedric Francois
-
Patent number: 8491909Abstract: The present invention comprises methods and compositions for immunotherapy. An aspect of the invention comprises administration of one or more allergens in compositions via oral and sublingual routes. Allergen compositions are administered in dosing intervals wherein the increase in the one or more allergens administered to the patient are provided in increasing volumes of a single concentration of at least one allergen.Type: GrantFiled: February 7, 2005Date of Patent: July 23, 2013Assignee: Greer Laboratories, Inc.Inventor: Robert E. Esch
-
Patent number: 8491911Abstract: This invention relates to the use of a pharmaceutical product comprising allergen and optionally an adjuvant for fast up-dosing in connection with allergy vaccination wherein a reduced number of injections are used. The invention also relates to the pharmaceutical product as such.Type: GrantFiled: October 15, 2009Date of Patent: July 23, 2013Assignee: Alk-Abello A/SInventors: Henrik Hugo Jacobi, Eike Gunther Wüstenberg, Lise Lund Mærkedahl
-
Patent number: 8491910Abstract: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerization. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.Type: GrantFiled: August 14, 2009Date of Patent: July 23, 2013Assignee: Circassia LimitedInventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
-
Publication number: 20130177594Abstract: The present invention provides a pharmaceutical composition capable of preserving and delivering an allergen having poor thermal stability without using gelatin as a stabilizer, and a method for producing the pharmaceutical composition. The present invention provides a pharmaceutical composition containing an allergen and additives selected from at least two groups from among group (A) consisting of polysaccharides having high formability; group (B) consisting of mono- to hexasaccharides, sugar alcohols thereof, maltodextrin, and polyvinylpyrrolidone; and group (C) consisting of viscous polysaccharides; wherein the additives have a stabilizing effect on the allergen.Type: ApplicationFiled: January 3, 2013Publication date: July 11, 2013Applicant: NITTO DENKO CORPORATIONInventor: NITTO DENKO CORPORATION
-
Publication number: 20130171233Abstract: The present invention provides liposomal compositions for inducing immune tolerance. The compounds typically comprise a liposome displaying a specific antigen and also a binding moiety for a sialic acid binding Ig-like lectin (Siglec) expressed on B cells. The invention also provides methods for inducing tolerance to a protein or polypeptide antigen (e.g., a protein antigen) in a subject. The methods involve administering to the subject a pharmaceutical composition that co-presents both the antigen and a glycan ligand for a Siglec expressed on B lymphocytes.Type: ApplicationFiled: July 29, 2011Publication date: July 4, 2013Inventors: James C. Paulson, Matthew MacAuley, David Nemazee
-
Publication number: 20130156812Abstract: A method of sublingually administering an effective amount of an antigenic composition to a mammal in order to produce a mucosal and systemic immune response.Type: ApplicationFiled: March 28, 2012Publication date: June 20, 2013Inventors: Stephen Hauer, Kristin Holm
-
Publication number: 20130156778Abstract: The present invention provides a dendritic cell modulatory protein which modulates, and preferably inhibits, the differentiation and/or maturation of mammalian dendritic cells. The invention also provides proteins comprising conserved motifs found in such proteins as well as pharmaceutical compositions comprising the dendritic cell modulatory protein and homologues and active fragments thereof, antibodies thereto and methods of treatment which utilise such proteins, homologues, fragments and antibodies.Type: ApplicationFiled: March 23, 2011Publication date: June 20, 2013Applicant: NATURAL ENVIRONMENT RESEARCH COUNCILInventors: Jonathan M. Austyn, Guido Paesen, Stephen Preston, Patricia Nuttal
-
Publication number: 20130149670Abstract: Compositions and methods of use for desensitizing a subject to an allergen via regions of the oral mucosa are provided.Type: ApplicationFiled: May 2, 2011Publication date: June 13, 2013Applicant: APELLIS PHARMACEUTICALS, INC.Inventor: Cedric Francois
-
Patent number: 8459046Abstract: The present invention relates to processes for the preparation of a batch of an active pharmaceutical ingredient, e.g. an allergen product. The invention also relates to a container comprising cryogranules of a liquid composition of an allergen product, and to a cryogranule of an allergen product. The processes feature formation of cryogranules using a container having therein a cryogenic medium (e.g. liquid nitrogen) and storage of the cryogranules in the same container. The cryogranules obtained can be stored and handled without prior freeze-drying.Type: GrantFiled: November 12, 2010Date of Patent: June 11, 2013Assignee: Alk-Abello A/SInventors: Martin Richter-Friis, Signe Andersen Kolmos
-
Publication number: 20130142830Abstract: This invention discloses an unexpected discovery that plasmacytoid dendritic cells (pDCs) may be segregated into immunogenic or tolerogenic species based on novel biomarkers discovered herein. Exemplary biomarkers include CD8?+?+, CD8?+??, CD8????, C1q, and IL-9R. For example, pDCs with CD8?+?+, CD8?+?? are tolerogenic and CD8???? is immunogenic. Also disclosed are isolated pDCs, compositions comprising the pDCs, methods for isolating the pDCs, methods for treating immune-hyper-reactivity, such as airway hyper-reactivity, food allergy, asthma, and autoimmune disorders, by using compositions containing tolerogenic antigen presenting cells, preferably pDCs disclosed herein. Also disclosed are methods for identifying tolerogenic antigen presenting cells by using one or more novel biomarkers disclosed herein, including RALDH expression, CD8?, CD8?C1qa, C1qc, and IL-9R. Also disclosed are methods for inducing Treg cells by using the pDCs disclosed herein.Type: ApplicationFiled: May 11, 2012Publication date: June 6, 2013Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Omid AKBARI, Vincent LOMBARDI
-
Publication number: 20130142778Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.Type: ApplicationFiled: March 25, 2011Publication date: June 6, 2013Applicant: IDERA PHARMACEUTICALS, INC.Inventors: SUDHIR AGRAWAL, EKAMBAR KANDIMALLA, MALLIKARJUNA PUTTA, Ireneusz Nowak, Nicola LaMonica, Weiwen Jiang, Michael Reardon, Tao Lan
-
Patent number: 8454964Abstract: Microparticles are disclosed which comprise a bead essentially consisting of a cross-linked carbohydrate and an antigen covalently linked thereto. The microparticle can be used for the treatment of disorders of the immune system and in diagnostic tests.Type: GrantFiled: April 17, 2003Date of Patent: June 4, 2013Assignee: Biomay AGInventors: Hans Groenlund, Johan Roennelid, Alex Karlsson-Parra, Marianne Van Hage-Hamsten, Rudolf Valenta, Susanne Vrtala, Ursula Wiedermann, Dietrich Kraft
-
Publication number: 20130121988Abstract: The present invention relates to a nucleic acid of the general formula (I): GlXmGn, which may be modified by a lipid. The invention relates further to a pharmaceutical composition containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). The present invention can relate to a vaccine, which corresponds to a pharmaceutical composition of the invention, wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention can relate to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune disease, allergies or cancer diseases.Type: ApplicationFiled: June 8, 2012Publication date: May 16, 2013Applicant: CureVac GmbHInventors: Ingmar Hoerr, Jochen Probst, Thomas Ketterer, Birgit Scheel
-
Patent number: 8440200Abstract: Methods for desensitization of a mammal suffering from IgE mediated allergy comprise the steps of: administering to said mammal a therapeutically effective amount of an immunogenic and hypoallergenic composition which comprises (i) a Phl p 6 molecule having an N-terminal truncation which makes the molecule at least lack IgE binding capacity, and/or (ii) a Phl p 6 molecule having a C-terminal truncation which makes the molecule at least lack IgE binding capacity, wherein the molecules of (i) and (ii), if employed in combination, together span the complete sequence of Phl p 6, and a pharmaceutically acceptable carrier.Type: GrantFiled: November 1, 2007Date of Patent: May 14, 2013Assignee: Phadia ABInventors: Rudolf Valenta, Susanne Vrtala, Sabine Stumvoll, Hans Grönlund, Monika Grote, Luca Vangelista, Annalisa Pastore, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft
-
Publication number: 20130101624Abstract: Linear polypeptide epitopes of hazelnut cor a 1 and celery api 1.0101 allergen of a sequence length of ten to fifteen amino acids for treatment and prevention of hazelnut or celery allergy are provided. Means and methods for diagnosing hazelnut or celery allergy, and for detecting hazelnut or celery allergens in a sample, are also provided.Type: ApplicationFiled: July 4, 2011Publication date: April 25, 2013Applicant: CHARITE UNIVERSITATSMEDIZIN BERLINInventors: Margitta Worm, Rudolf Volkmer, Bernhard Ay, Elvira Ruppel
-
Patent number: 8420095Abstract: Microspheres containing antigens for allergy therapy, the microspheres having a binding constant of 1×104 M?1 toward a specific carbohydrate residue of intestinal and/or nasal epithelial cells.Type: GrantFiled: April 28, 2004Date of Patent: April 16, 2013Assignee: Biomay Produktions-und Handels AGInventors: Erika Jensen-Jarolim, Franziska Roth-Walter, Franz Gabor
-
Patent number: 8420097Abstract: The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilized for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.Type: GrantFiled: July 9, 2010Date of Patent: April 16, 2013Assignee: Merck Patent GmbHInventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
-
Publication number: 20130089572Abstract: The present disclosure relates to methods of reducing the onset of allergies. In certain embodiments, the method includes administering to an infant a nutritional composition that includes a fat or lipid source, a carbohydrate source, a protein source comprising whey and casein proteins and, optionally, a probiotic. In certain embodiments, the whey:casein ratio in the protein source is from about 50:50 to about 70:30 and the degree of hydrolysis of the proteins included in the protein source is from about 4% to about 10%.Type: ApplicationFiled: October 11, 2011Publication date: April 11, 2013Applicant: Mead Johnson Nutrition CompanyInventors: Jon A. Vanderhoof, Deolinda Scalabrin
-
Publication number: 20130084306Abstract: Described are vaccines having one or more antigens cholesterol and CpG. Aspects of the invention relate to the use of the vaccines of the invention for the treatment and/or prevention of human and animal disorders.Type: ApplicationFiled: May 27, 2011Publication date: April 4, 2013Applicant: Coley Pharmaceutical Group Inc.Inventors: Heather Lynn Davis, Risini Weeratna, Paul J. Dominowski
-
Patent number: 8409582Abstract: Disclosed are major allergenic proteins in cashew nut, which are legumin-like proteins and 2S albumins. Also disclosed is a polypeptide allergen in the 7S superfamily, which includes vicilin-like and sucrose binding proteins. Several linear epitopes of the cashew nut are identified and characterized. The invention further discloses the sequence of cDNA encoding the allergenic polypeptide, the allergen being designated Ana o 1, and also describes the characterization of the expressed recombinant polypeptide and associated methods employing the polypeptide.Type: GrantFiled: February 10, 2012Date of Patent: April 2, 2013Assignee: Florida State University Research Foundation, Inc.Inventors: Kenneth Roux, Shridhar Sathe, Suzanne Teuber
-
Publication number: 20130064854Abstract: A method for treating a patient suffering from allergy by desensitizing the patient to an allergen component that includes orally, sublingually, or intranasally administering to the patient a therapeutically effective amount of an immunomodulating composition and successively repeating the administration at a selected interval with the therapeutically effective amount of each successive administration comprising an increasing amount of the allergen component. The composition includes an amount of the allergen component that is sufficient to impart an immune response and a pharmaceutically acceptable carrier that is at least substantially free of phenol. The successive repeating occurs a sufficient number of times to reduce patient sensitivity to the allergen component, and avoids or minimizes oral adverse effects. An immunomodulating product is also described.Type: ApplicationFiled: September 7, 2012Publication date: March 14, 2013Applicant: Antigen Laboratories, Inc.Inventors: Robert W. Pomrenke, William Goldberg, Patrick D. McGrath
-
Publication number: 20130058977Abstract: Disclosed are induced tolerogenic dendritic cells (itDCs) produced by combining itDCs with externally loadable MHC Class I-restricted epitopes, as well as related compositions and methods.Type: ApplicationFiled: April 27, 2012Publication date: March 7, 2013Applicant: Selecta Biosciences, Inc.Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
-
Publication number: 20130058978Abstract: Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that generate regulatory B cells, as well as related compositions and methods.Type: ApplicationFiled: April 27, 2012Publication date: March 7, 2013Applicant: Selecta Biosciences, Inc.Inventor: Roberto A. Maldonado
-
Publication number: 20130059009Abstract: Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that are produced from combining itDCs with antigen in particulate form, as well as related compositions and methods.Type: ApplicationFiled: April 27, 2012Publication date: March 7, 2013Applicant: Selecta Biosciences, Inc.Inventors: Takashi Kei Kishimoto, Roberto A. Maldonado, Christopher Fraser, David H. Altreuter
-
Publication number: 20130058975Abstract: Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing undesired humoral immune responses, as well as related compositions and methods.Type: ApplicationFiled: April 27, 2012Publication date: March 7, 2013Applicant: Selecta Biosciences, Inc.Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
-
Publication number: 20130058970Abstract: Disclosed are induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods, for reducing systemic inflammatory cytokines.Type: ApplicationFiled: April 27, 2012Publication date: March 7, 2013Applicant: Selecta Biosciences, Inc.Inventors: Takashi Kei Kishimoto, Roberto A. Maldonado
-
Publication number: 20130058976Abstract: Disclosed are allergen-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods.Type: ApplicationFiled: April 27, 2012Publication date: March 7, 2013Applicant: Selecta Biosciences, Inc.Inventors: Takashi Kei Kishimoto, Roberto A. Maldonado
-
Publication number: 20130058974Abstract: Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing CD8+ T cell immune responses, as well as related compositions and methods.Type: ApplicationFiled: April 27, 2012Publication date: March 7, 2013Applicant: Selecta Biosciences, Inc.Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
-
Publication number: 20130045232Abstract: A mucosal vaccine producing an antigen-specific mucosal IgA and a blood IgG in the levels capable of exerting an effective immune induction and an infection-preventing effect, which comprises: (a) an AD vehicle consisting of a synthetic peptide and a lipid(s), wherein the synthetic peptide consisting of the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20); (b) a carboxylvinyl polymer; and, (c) an antigenic protein, in an amount incapable of producing a sufficient mucosal IgA and blood IgG for exerting an effective immune induction and an infection-preventing effect when used by itself. The mucosal vaccine of the invention has an antibody producing ability which is more potent than those of mucosal vaccines of the prior art, and as a result it can exert an excellent effect even with an extremely small amount of an antigen.Type: ApplicationFiled: March 1, 2011Publication date: February 21, 2013Inventors: Hiroshi Kido, Dai Mizuno
-
Publication number: 20130045267Abstract: Methods are provided for modulating expression of claudin-1 and/or claudin-23, for purposes of regulating formation of tight junctions in keratinocytes or other types of cells such as antigen presenting cells (e.g., dendritic cells and Langertians cells), by either increasing or decreasing expression of claudin-1 and/or claudin-23. Also provided are transdermal formulations that decrease expression of claudin-1 and/or claudin-23, thereby diminishing tight junction formation in cells expressing claudin-1 and/or claudin-23, as well as a transdermal patch for delivering the same.Type: ApplicationFiled: February 7, 2011Publication date: February 21, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Lisa A. Beck, Anna De Benedetto
-
Publication number: 20130028850Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents; and the amount of viscosity modifying agents can optionally be reduced by at least an amount by weight that would have increased the viscosity of the carrier without the tetracycline antibiotic by at least 30%; wherein the tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracyclineType: ApplicationFiled: October 1, 2010Publication date: January 31, 2013Applicant: FOAMIX LTD.Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan